Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice-Reference-Cited by-同舟云学术

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice

Published:2023-07-23 Issue:9 Volume:13 Page:1893-1907
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Gooderham Melinda J.^ORCID,Pink Andrew E.^ORCID,Simpson Eric L.^ORCID,Silverberg Jonathan I.^ORCID,Güler Erman,Watkins Melissa

Funder

Pfizer Inc.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-023-00948-6.pdf

Reference26 articles.

1. Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, et al. Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem. 2018;61:1130–52.

2. Cibinqo (abrocitinib). Prescribing information. Pfizer Labs; 2022.

3. European Medicines Agency. Cibinqo® (abrocitinib). Summary of product characteristics (SmPC). Pfizer Europe MA EEIG; 2021.

4. Cibinqo 100 mg film-coated tablets. Summary of product characteristics. Pfizer Ltd.; 2021.

5. Cibinqo™ (abrocitinib) tablets, for oral use 50 mg 100 mg 200 mg. Prescribing information. Pfizer Japan Inc.; 2021.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate‑to‑severe atopic dermatitis in randomized, double‑blind and placebo‑controlled trials: A systematic review and a meta‑analysis;Biomedical Reports;2024-03-29